Sollis Therapeutics Announces the First Patient Enrolled in a Phase 3 Clinical Trial of Clonidine Micropellet for Sciatica
Sollis Therapeutics, Inc., an Ohio-based interventional pain therapeutics company, announced that the first patient was enrolled in the RePRIEVE-CM trial, a Phase 3 clinical trial evaluating the efficacy and safety of the extended release non-opioid, non-steroid clonidine micropellet for the treatment of sciatica pain.